FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 70466 - Tobacco Products Scientific Advisory Committee - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	Tobacco Products Scientific Advisory Committee	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	70466
Original Establishment Date		Committee Status	Chartered
Actual Termination Date		Committee URL	http://www.fda.gov/AdvisoryCommittees/Committee...
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	12
Terminated This FY	No	Designated Fed Officer Position Title*	Designated Federal Officer
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	8/12/2009	Designated Federal Officer First Name*	Rachel
Date Of Renewal Charter		Designated Federal Officer Middle Name	Mi
Projected Termination Date		Designated Federal Officer Last Name*	Jang
Exempt From Renewal*	Yes	Designated Federal Officer Suffix
Specific Termination Authority		Designated Federal Officer Phone*	(301)796-1288
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*	(240)-276-3655
Specific Establishment Authority*	H.R. 1256 Family Smoking Prevention and Tobacco Control Act; FD&C 21 U.S.C. 387q	Designated Federal Officer Email*	rachel.jang@fda.hhs.gov
Effective Date Of Authority*	6/22/2009
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides advice, information and recommendations to the Commissioner of Food and Drugs.
How is membership balanced?*	Members are experts in the fields of medicine, medical ethics, science, or technology involving the manufacture, evaluation, or use of tobacco products. One voting member is an officer or employee of a state or local government or of the Federal Government. One voting member is a representative of the general public. In addition to the voting members, the Committee includes 3 non-voting members who are identified with industry interests. These members include one representative of the tobacco manufacturing industry, one representative of the interests of tobacco growers, and one representative of the interests of the small business tobacco manufacturing industry. This final position can be filled on a rotating, sequential basis by representatives of different small business tobacco manufacturers based on areas of expertise relevant to the topics being considered by the Committee.
How frequent & relevant are cmte mtgs?*	The Committee did not meet in FY25. There are two meetings projected for FY26.
Why advice can't be obtained elsewhere?*	Members of the committee are drawn from academia, research, and/or clinical practice. They provide advice and input that FDA considers as part of its regulatory decision-making. The alternate means of obtaining this advice would be to hire large numbers of scientists on a full-time basis at great expense to the government.
Why close or partially close meetings?	There were no closed meetings to report in FY 25.
Recommendation Remarks	There were no committee meetings in FY 2025. Time was also devoted to reviewing applications for new nominees, maintaining associated records for these activities, and streamlining paper processes within FDA. In addition, time was spent in the routine care and maintenance of the committee: the development of a financial report for this website; updating the roster and number of vacancies on our website; completing the annual ethics report; reviewing financial disclosures of current members and providing ethics training.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	Yes	Action Issued New Regulations	Yes
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	No	Action Other	Yes
Outcome Increased Customer Satisfaction	Yes	Action Comment	The Agency will use the committee's advice in implementing the Family Smoking Prevention and Tobacco Control Act.
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	NA	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	The utilization of the Tobacco Products Scientific Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency and to obtain the services of these experts only on an as needed bases rather than on a full time basis. The service of the committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.	Grants Review Comment	N/A
Number Of Recommendations*	10	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	The committee made 10 recommendations from FY09 through FY23.	Access Agency Website	Yes
% of Recs Fully Implemented*	84.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	10.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.	Access Other	No
Agency Feedback*	Yes	Access Comment	N/A
Agency Feedback Comment*	When appropriate, information is made available to the public. Actions related to guidance documents or other general matters or issues are available publicly when implemented.	Narrative Description*	FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Tobacco Products Scientific Advisory Committee supports FDA's strategic priorities by reviewing and evaluating safety, dependence, and health issues relating to tobacco products and making recommendations to the Commissioner of Food and Drugs.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:55 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Health Public Health Safety Medicine Health and Health Research Social Sciences Social Sciences

Custom Links

Committee Level Reports